Advances in the management of irritable bowel syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 4, 2002, Pages 503-507

  Kellow, John E ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Diagnostic criteria; Enteric nervous system; Irritable bowel syndrome; Pathophysiological mechanisms; Pharmacological treatment; Psychological approaches; Symptoms patterns

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALOSETRON; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDIARRHEAL AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; FEDOTOZINE; HERBACEOUS AGENT; LACTULOSE; LAXATIVE; LOPERAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PRUCALOPRIDE; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SORBITOL; SPASMOLYTIC AGENT; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; BEHAVIOR; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DIET THERAPY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GASTROENTERITIS; HUMAN; INTESTINE INNERVATION; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; LIFESTYLE; MOTOR DYSFUNCTION; NEUROMUSCULAR FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RELAXATION TRAINING; SENSORY DYSFUNCTION; SYMPTOM; T LYMPHOCYTE;

EID: 0036097590     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02759.x     Document Type: Conference Paper

References (15)

1. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures
2. Towards a positive diagnosis of the irritable bowel syndrome
3. Rome II: A multinational consensus document on functional gastrointestinal disorders
4. Division of irritable bowel syndrome into subgroups on the basis of daily recorded systems in two outpatients samples
5. Principles of applied neurogastroenterology: Physiology/motility-sensation
6. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome
7. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome
8. Chronic stress impairs rat growth and jejunal epithelial barrier function: Role of mast cells
9. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome
10. Postprandial plasma 5-hydroxytryptamine in diarrhea predominant irritable bowel syndrome: A pilot study
11. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials
12. Treatment of the irritable bowel syndrome with Chinese herbal medicine: A randomised controlled trial
13. Psychological treatments for irritable bowel syndrome: A critique of controlled clinical trials
14. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo controlled trial
15. New pharmacological agent review: Tegaserod